Is there an answer? What is the mechanism for melasma that so commonly accompanies human pregnancy?

IUBMB Life

Volumn 58, Issue 1, 2006, Pages 55-57

  Costin, Gertrude Emilia ^a,c   Birlea, Stanca Ariana ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Zalau Hospital   (Romania)

^c Avon Products Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; ANTICONVULSIVE AGENT; AZELAIC ACID; CORTICOTROPIN; DOPACHROME TAUTOMERASE; ENDOTHELIN 1; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FREE RADICAL; HYDROQUINONE; INTERLEUKIN 1; MONOPHENOL MONOOXYGENASE; ORAL CONTRACEPTIVE AGENT; PHOTOSENSITIZING AGENT; PROGESTERONE; RETINOIC ACID; SUNSCREEN;

APPLICATION SITE HYPERPIGMENTATION; APPLICATION SITE INFLAMMATION; CELL PROLIFERATION; CHLOASMA; CLINICAL FEATURE; DNA SYNTHESIS INHIBITION; ENZYME ACTIVITY; EPILEPSY; ESTROGEN ACTIVITY; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; GENETIC ASSOCIATION; HORMONE ACTION; HUMAN; HYPERPIGMENTATION; KERATINOCYTE; LIPID PEROXIDATION; LIVER DISEASE; MELANOCYTE; MELANOGENESIS; NUTRITIONAL HEALTH; OVARY INSUFFICIENCY; OVARY TUMOR; PARASITOSIS; PATHOPHYSIOLOGY; PHOTOALLERGY; PHOTOTOXICITY; PREGNANCY; PROGESTERONE BLOOD LEVEL; SEX DIFFERENCE; SHORT SURVEY; SKIN ATROPHY; SKIN EPITHELIUM; SKIN SCAR; SUN EXPOSURE; SUNLIGHT PROTECTION; THIRD TRIMESTER PREGNANCY; THYROID DISEASE; ULTRAVIOLET B RADIATION; ULTRAVIOLET RADIATION; UPREGULATION; YAG LASER; FEMALE; MELANOSIS; METABOLISM; REVIEW;

FEMALE; HUMANS; MELANOSIS; PREGNANCY;

EID: 33645103290     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1080/15216540500417020     Document Type: Short Survey

References (24)

1. Guevara, I. L., and Pandya, A. G. (2003) Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma. Int. J. Dermatol. 42, 966-972.
2. Smith, A. G., Shuster, S., Thody, A. J., and Peberdy, M. (1977) Chloasma, oral contraceptives, and plasma immunoreactive beta-melanocyte stimulating hormone. J. Invest. Dermatol. 68, 169-170.
3. Wong, R. C., and Ellis, C. N. (1984) Physiologic skin changes in pregnancy. J. Am. Acad. Dermatol. 8, 929-940.
4. Jimbow, M., and Jimbow, K. (1989) Pigmentary disorders in oriental skin. Clin. Dermatol. 7, 11-27.
5. Katsambas, A., Antoniou, Ch., Katsarou, A., and Stratigos, J. (1987) Melasma: a clinical study of 210 patients. 17th World Congress of Dermatology. Volume abstracts, 177-178.
6. Katsambas, A., and Antoniou, Ch. (1995) Melasma. Classification and treatment. J. Eur. Acad. Dermatol. Venereol. 4, 217-223.
7. Goh, C. L., and Dlova, C. N. (1999) A retrospective study on the clinical presentation and treatment outcome of melasma in a tertiary dermatological referral centre in Singapore. Singapore Med. J. 40, 455-458.
8. Vazquez, M., Maldonado, H., Benmaman, C., and Sanchez, J. L. (1988) Melasma in men. A clinical and histologic study. Int. J. Dermatol. 27, 25-27.
9. Sies, H., and Stahl, W. (2004) Nutritional protection against skin damage from sunlight. Annu. Rev. Nutr. 24, 173-200.
10. Luger, T. A., and Schwarz, T. (1990) Evidence for an epidermal cytokine network. J. Invest. Dermatol. 95 (Suppl.), 100S-104S.
11. Schauer, E., Trautinger, F., Kock, A., Schwarz, A., Bhardwaj, R., Simon, M., Ansel, J. C., and Luger, T. A. (1994) Proopiomelanocortin-derived peptides are synthesized and released by human keratinocytes. J. Clin. Invest. 93, 2258-2262.
12. Kang, W. H., Yoon, K. H., Lee, E. S., Kim, J., Lee, K. B., Yim, H., Sohn, S., and Im, S. (2002) Melasma: histopathological characteristics in 56 Korean patients. Br. J. Dermatol. 146, 228-237.
13. Grimes, P. E., Yamada, N., and Bhawan, L. (2005) Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am. J. Dermatopathol. 27, 96-101.
14. Parker, F. (1981) Skin and hormones. In Textbook of Endocrinology, (Williams, R. H., ed.), pp. 1088-1091. W.B. Saunders Co., Philadelphia,
15. Grimes, P. E. (1995) Melasma. Etiologic and therapeutic considerations. Arch. Dermatol. 131, 1453-1457.
16. 3, alpha-melanocyte stimulating hormone, and beta-estradiol. J. Invest. Dermatol. 91, 593-598.
17. Kippenberger, S., Loitsch, S., Solano, F., Bernd, A., and Kaufmann, R. (1998) Quantification of tyrosinase, TRP-1, and TRP-2 transcripts in human melanocytes by reverse transcriptase-competitive multiplex PCR-regulation by steroid hormones. J. Invest. Dermatol. 110, 364-367.
18. McLeod, S. D., Ranson, M., and Mason, R. S. (1994) Effects of estrogens in human melanocytes in vitro. J. Steroid Biochem. Mol. Biol. 59, 9-14.
19. Zava, D. T., and Goldhirsch, A. (1983) Estrogen receptor in malignant melanoma: fact of artefact? Eur. J. Cancer Clin. Oncol. 19, 1151-1159.
20. Jee, S. H., Lee, S. Y., Chiu, H. C., Chang, C. C., and Chen, T. J. (1994) Effects of estrogen and estrogen receptors in normal human melanocytes. Biochem. Biophys. Res. Commun. 199, 1407-1412.
21. Kuiper, G. G., Carlsson, B., Grandien, K., Enmark, E., Häggblad, J., Nilsson, S., and Gustafsson, J.-Å. (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138, 863-870.
22. Denton, C. R., Lerner, A. B., and Fitzpatrick, T. B. (1952) Inhibition of melanin formation by chemical agents. J. Invest. Dermatol. 18, 119-135.
23. Fitton, A., and Goa, K. L. (1991) Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs 41, 780-798.
24. Tung, R. C., Bergfeld, W. F., Vidimos, A. T., and Remzi, B. K. (2000) Alpha-hydroxy acid-based cosmetic procedures. Guidelines for patient management. Am. J. Clin. Dermatol. 1, 81-88.